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Mutation analysis of the BRCA1 and BRCA2 genes has become
widely available to hereditary breast and ovarian cancer families
(HBOC) or breast-cancer-only families (HBC) in North America
and Europe. To date, hundreds of these families have been identi-
fied with BRCA mutations and the majority has received coun-
selling regarding the test results. Follow-up care of mutation
carriers has focused on cancer surveillance and surgical options
(Burke et al, 1997). However, little is known about the impact
carrier status has on the development of depression, or the
resulting changes in the individual’s body image (Lerman et al,
1996, 1997; Croyle et al, 1997; Lynch et al, 1997). In the Lerman
et al (1996) study population, 18% stated their intent to undergo
prophylactic mastectomy (PM) and 33% stated their intent to
under prophylactic oophorectomy (PO). The motivational issues
involved in deciding for or against prophylactic surgery, however,
still await detailed study. Similarly, hardly anything is known
about the feelings associated with this decision or their effect on
the individual’s quality of life in general.
The major aim of this study was to study the attitude of mutation
carriers in regard to PM and PO. Furthermore, it assessed the
short-term effect of knowledge about carrier status on the occur-
rence of depression.
PATIENTS AND METHODS
Study population
A total of 138 individuals, from 35 families, that had been selected
and counselled through the genetic counselling service of the
Division of Senology, University of Vienna, were enrolled on the
basis of previously detected BRCA1 or BRCA2 mutations. None of
the family members had received the results of the BRCA testing.
All individuals who requested their results were informed about
this study. Family members who elected to participate gave their
written consent. Prior to mutation result disclosure and coun-
selling study participants received the first questionnaire of this
study. The sequence in which the various elements of the survey
were conducted is depicted in Figure 1.
All female mutation carriers are examined every 6 months for
the purposes of cancer surveillance and psychosocial follow-up.
The observation period for this study began in January 1996 and is
currently still being continued. This study was approved by the
University of Vienna Institutional Review Board.
Attitude of mutation carriers towards the option of PM
and/or PO
Female mutation carriers received a questionnaire comprising 12
items concerning PM and 11 items concerning PO to be rated on a
five-point scale. Since the relevant literature does not provide a
standardized questionnaire on this subject, two special question-
naires were developed on the basis of past conversations with
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attitude that Austrian mutation carriers demonstrate towards PM
and PO. This questionnaire addressed the following issues:
general willingness to undergo surgery, willingness to undergo
PM/PO, surveillance vs PM/PO, feelings associated with PM/PO,
effect on the quality of life and motivation regarding potential
PM/PO.
Depression symptoms
The validated self-rating depression scale (SDS) (Zung, 1986)
consisted of 20 items requiring patients to indicate whether each
one applied ‘never’, ‘occasionally’, ‘frequently’ or ‘always’. This
scale has a split-half reliability of r = 0.73 and has been shown to
correlate with the Hamilton depression scale. It is associated with
clinical ratings of the severity of depression. On this measure,
scores ranging from 1 to 40 are considered normal, mild depres-
sion falls between 41 and 47, mild to severe between 48 and 55,
with scores above 55 indicating severe depression.
Statistical analysis
For description of the data, frequencies and relative frequencies were
given. Continuous variables were expressed as means ± standard
deviation (s.d.) The ‘SDS-Index’ was computed according to Zung
(1986). Wilcoxon two-sample tests were used to compare carriers
versus non-carriers and affected versus non-affected carriers. The
SAS® statistical software system was used for computation. A 
P-value < 0.05 was considered to indicate statistical significance.
RESULTS
Of 138 family members from 35 mutation families counselled in
regard to hereditary breast- and ovarian cancer, and subsequently
tested for BRCA1 and  BRCA2 mutations, 93 (67%) family
members requested the test results. Of these, 90 (97%) family
members agreed to participate in the study and received the
questionnaires according to Figure 1. However, some respondents
chose to return certain questionnaires not at all or with a number of
questions left unanswered. Fifty-nine of the study participants
were mutation carriers: two male (one affected and one non-
affected) and 57 female mutation carriers. Of the female mutation
carriers, 33 had already developed cancer (affected carriers) and
24 were still healthy (non-affected carriers). Thirty-one were non-
carriers: three male and 28 female.
Sociodemographic factors
The average age (s.d.) of the study participants was 38 (16). All
respondents were of Austrian origin, 94% were female, 73%
married. All of them had completed at least 8 years of (compul-
sory) school education, 43% had finished secondary school with
the ‘Matura’ diploma after an additional 4 years of school. All
were either employed, students or active as housewives. Due to
Austria’s publicly funded health care system, all participants were
covered by health insurance.
Prophylactic mastectomy (Table 1)
Thirty-four carriers (21 affected and 13 non-affected) completed
the questionnaires concerning PM. All carriers showed a general
willingness to undergo surgery in case of serious illness. However,
PM was considered by only 21% of mutation carriers: one (8%) of
the non-affected carriers and six (29%) of affected carriers. Of the
latter, one had already obtained PM of the contralateral breast, and
bilateral mastectomy had been performed on two because of
bilateral cancer before learning about their carrier status. After
mutation result disclosure, one affected carrier had bilateral
mastectomy after unilateral cancer and two intended to do so.
Ninety-two per cent of non-affected carriers and 80% of the
affected carriers showed a preference for surveillance. The
following feelings were caused by or associated with PM: 69% of
non-affected carriers experienced anxiety and 38% felt helpless,
46% regarded PM as an invasion of their privacy. The majority of
affected and non-affected carriers were afraid PM would impair
the quality of their life. In regard to what would favourably influ-
ence their decision to undergo PM, 62% of affected carriers named
the death of close relatives due to breast cancer, 52% the reduced
risk of developing cancer and 48% their fear of dying of cancer.
Fifty-two per cent of all affected and 69% of non-affected carriers
were first informed about the PM option during the course of the
information and counselling sessions at our department (data not
shown).
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Patient selection
First questionnaire and counselling
After 6–8 weeks
After 3 months
1. Depression questionnaire (baseline) (n  =  81*)
2. Mutation result disclosure and genetic
counselling (n  =  90)
Carriers and non-carriers
Carriers and non-carriers
Carriers
1. Fulfilment of selection criteria (n  = 138)
2. Information about study (n  = 93)
3. Written informed consent (n  = 90)
Depression questionnaire (n  =  66*)
Attitude towards prophylactic mastectomy
and oophorectomy (n  = 34* and n  = 30*)
Figure 1 Study design. *Some respondents chose to return certain
questionnaires not at all or with a number of questions left unansweredProphylactic oophorectomy (Table 2)
Thirty carriers (17 affected and 13 non-affected) completed the
questionnaires concerning PO. Fifty per cent of all carriers showed
a positive attitude towards PO (53% affected and 46% non-
affected carriers). As in the case of PM, 76% of affected and 92%
of non-affected carriers preferred surveillance. In both groups
some participants showed a positive attitude towards PO, but they
also marked in the following question a preference for surveil-
lance. Subsequent to becoming part of this study, one healthy and
four affected carriers had undergone PO. Fifty-three per cent of
non-affected carriers experienced fear in conjunction with the idea
of PO. The majority of affected and 31% of non-affected carriers
showed concern about a potential impairment of the quality of
their lives. The majority of affected and non-affected carriers
agreed with the listed motivations in favour of PO.
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Table 1 Attitude of female BRCA mutation carriers toward prophylactic mastectomy (PM), n = 34a
Items Affected carriers, Non-affected
n = 21 carriers, n = 13
I + II + III IV + V I + II + III IV + V
General willingness to undergo surgery 21 0 13 0
Attitude towards PM 6 15 1 12
Surveillance vs PM, considering that 17 4 12 1
surveillance does not provide complete
protection
Feelings caused by/associated with PM
1. Anxiety 13 8 9 1
2. Helplessness 8 13 5 2
3. Invasion of privacy 11 10 6 3
Effect of PM on the quality of life
1. General 15 2 6 1
2. Female identity 16 4 6 2
3. Sexuality 13 7 7 1
Motivation in favour of PM
1. Future plans 8 10 1 8
2. Reduced risk of developing cancer 11 8 4 4
3. Fear of dying of BC 10 5 6 3
Decision to undergo PM influenced by the 7 11 4 9
option of reconstructive surgery
Reconstructive surgery will definitely be 8 11 9 3
sought following potential PM
I = certainly, II = probably, III = likely, IV = unlikely, V = does not apply. There were no significant differences
between the two groups for any item (Fisher’s exact test). aSome respondents chose to return certain
questionnaires with a number of questions left unanswered.
Table 2 Attitude of female BRCA mutation carriers toward prophylactic oophorectomy (PO), n = 30a
Items Affected carriers, Non-affected
n = 17 carriers, n = 13
I + II + III IV + V I + II + III IV + V
General willingness to undergo surgery 17 0 13 0
Attitude towards PO 9 7 6 7
Surveillance vs. PO, considering that 13 3 12 1
surveillance does not provide complete
protection
Feelings caused by/associated with PO
1. Anxiety 8 6 7 2
2. Helplessness 6 8 3 3
3. Invasion of privacy 6 8 4 5
Effect of PO on the quality of life
1. General 9 2 4 4
2. Female identity 10 6 2 6
3. Sexuality 9 7 2 6
Motivation in favour of PO
1. Future plans 7 6 3 5
2. Reduced risk of developing cancer 10 5 7 2
3. Fear of dying of BC 10 5 6 3
In case of PO also hysterectomy 10 5 10 3
I = certainly, II = probably, III = likely, IV = unlikely, V = does not apply. There were no significant differences
between the two groups for any item (Fisher’s exact test). aSome respondents chose to return certain
questionnaires with a number of questions left unanswered.Depression symptoms
At baseline, prior to being counselled in regard to their carrier
status, SDS questionnaires from 81 participants were available.
Thirty-nine per cent of all carriers (47% affected carriers and 29%
non-affected carriers) and 19% of non-carriers showed mild to
severe depression. There was no significant difference between
carriers and non-carriers at baseline (P = 0.07) (Figure 2A).
However, between affected and non-affected carriers a highly
significant difference could be noticed (P = 0.0003) (Figure 2B).
Six to 8 weeks after mutation result disclosure, the SDS ques-
tionnaire was returned by 66 patients. Overall scores were similar
between carriers and non-carriers (P = 0.8). Affected carriers still
presented a significantly higher depression score than non-affected
carriers (P = 0.02). The overall score between baseline and 
6 weeks after mutation results disclosure decreased for carriers 
(P = 0.3; Wilcoxon signed rank test), whereas depression scores
for non-carriers increased (P = 0.05).
DISCUSSION
Prophylactic surgery
At 21%, the percentage of Austrian mutation carriers who would
undergo PM conforms to previously published data. Lerman et al
(1996) and Lynch et al (1997) found a percentage of 18% and 35%
respectively, in a North American collective, whereas in the
Netherlands, Meijers-Heijboer et al (1997) determined a
percentage of 57%. In our study population the prevailing rejec-
tion of PM (79%) reflects the expectation that this procedure will
impair the quality of the woman’s life (female identity, relation-
ship, sexuality, leisure activity and emotional balance). In addi-
tion, PM tended to be associated with negative feelings such as
fear and the invasion of one’s privacy. In our findings, it was
predominantly affected carriers who opted for PM but only one of
the non-affected carriers. This result might be specific to the
Austrian attitude towards prophylactic surgery. The assumption
that non-affected Austrian carriers are disinclined to have a
‘healthy’ organ removed was supported by our findings.
Regarding motivation for PM, only 30% of the non-affected
carriers named the reduced risk of developing cancer (as opposed
to 52% of the affected carriers), or the fear of dying of breast
cancer (48% of the affected carriers). In this context, it is impor-
tant to note that even PM does not offer 100% certainty (Hartmann
et al, 1999). It remains to be seen to which degree this negative
attitude towards PM was related to the fact that 59% of all carriers
were first advised of the option of PM in the course of the
information and counselling session. In the USA and in The
Netherlands, on the other hand, patients have better access to
information on this subject via the media and, consequently, tend
to be more familiar with it.
The significantly higher degree of acceptance of PO (53% of
affected carriers and 46% of non-affected carriers) was due to the
patients’ expectation that the quality of their lives was not likely to
be impaired (in particular as far as female identity was concerned).
On the one hand, negative feelings associated with PO tended to
be less pronounced, while on the other hand motivation to undergo
PO was perceived as stronger. Among the study population of
Lerman et al (1996) and Lynch et al (1997) the acceptance of PO
was determined to be 33% and 76%, respectively, whereas
Meijers-Heijboer et al (1997) found a rate 61%. Certainly, the rate
of acceptance of PO also reflects the high standard of available
information about the limited diagnostic possibilities and doubtful
prognosis in the face of ovarian cancer.
Depression symptoms
Prior to disclosure of the result of mutational analysis, 39% of all
carriers showed depressive symptoms. The high frequency of
depressive symptoms prior to counselling is probably due to the
high percentage of already affected carriers (55%) (Schover, 1991;
Thompson and Shear, 1998). Six to 8 weeks after mutation result
disclosure, overall scores of carriers were slightly decreased. No
doubt, the reasons for this are somewhat complicated. First,
learning about one’s test result may reduce prolonged uncertainty
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Figure 2 (A)  Depression scores of carriers versus non carriers before and
6–8 weeks after mutation result disclosure. (B) Depression scores of affected
carriers versus non-affected carriers before and 6–8 weeks after mutation
result disclosure
B
Aand thereby enhance quality of life independent of carrier status, as
proved to be the case with genetic testing for Huntington’s disease
(Wiggins et al, 1992; Bundey, 1997). This effect has a particular
bearing on our study population because the majority of family
members had already decided to undergo testing prior to genetic
counselling. In this context, contributing factors may lie in the
psychological robustness of those individuals choosing to take the
test in the first place (Lerman et al, 1998), and the adherence to a
careful protocol, as observed previously with Huntington’s disease
(Codori et al, 1994). Secondly, the majority of our carriers (55%)
were already affected with cancer at the time of this study. For
these women, learning about their carrier status did not actually
represent a new development. Thirdly, one should not disregard
the fact that HBOC/HBC families show a considerable awareness
of the possibility of genetic predisposition. Most family members
usually know several relatives who have developed or succumbed
to breast or ovarian cancer and, therefore, they have come into
repeated contact with this issue.
Surprisingly non-carriers showed an increase of depression
scores after mutation result disclosure. In contrast, other studies
(Lerman et al, 1998, Dudok deWit et al, 1998) found a decrease in
depression scores in non-carriers from families with hereditary
breast and ovarian cancer. However, the failure to experience relief
after being identified as a non-carrier has been described for
Huntington’s disease. Tibben et al (1992) and Huggins et al (1992)
presented data of non-carriers that express survivor guilt,
emotional numbness and difficulty in coping with the effects of the
test results on the family system. Our data suggest that survivor
guilt might also be present in Austrian non-carriers and it will need
further investigation with questionnaires addressing survivor guilt.
We conclude that in Austria, prophylactic surgery continues to
be a comparatively new concept. The questionnaires specifically
developed to address this subject illustrate the difference in the
patients’ reactions: the option of having PM performed was associ-
ated with fear and a negative impact on the quality of life by
affected and non-affected individuals alike. Prophylactic
oophorectomy was accepted by 50% of the participants; in
general, it was not associated with an impairment of the quality of
life. These results stress the importance of conducting counselling
for surgical options with great care and consideration.
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